ClinicalTrials.gg
RecruitingNCT05843630Updated May 6, 2023

Radiomic Modeling in Differentiating Uncomplicated From Complicated Acute Appendicitis

An observational study in Acute Appendicitis, sponsored by Kecheng Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Kecheng Zhang · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Appendicitis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Appendicitis · China.

Started
2023
with 1 other
Observational
4 of 17
3 open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Kecheng Zhang

Among the 17 studies in Appendicitis with a site in China, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 10th registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

6 of the 17 studies in Appendicitis with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Appendicitis with a site in China, or all of them as a file.
02

Study summary

Non-operative management (NOM) with antibiotics may be a safe alternative to surgery for uncomplicated appendicitis, but preoperative differentiation between uncomplicated and complicated appendicitis is challenging. The study aimed to develop a clinical-radiomics nomogram to distinguish uncomplicated from complicated appendicitis.

03

Conditions studied

  • Acute Appendicitis

Keywords

  • acute appendicitis
  • diagnosis
  • nomogram
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All adults with pathologically diagnosed as acute appendicitis after appendectomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed as acute appendicitis after appendectomy between January 2021 and December 2022.

Exclusion criteria

Exclusion Criteria:

  • age less than 18 years (no upper age limit);
  • without CT examination within a week before surgery;
  • difficult to outline the contours of the appendix due to inflammatory exudate;
  • lack of clinical information.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Training cohort

    Model construction based on training cohort

    Diagnostic Test: without

  • Validation cohort 1

    Model validation in an independent validation cohort 1

    Diagnostic Test: without

  • Validation cohort 2

    Model validation in an independent validation cohort 2

    Diagnostic Test: without

Interventions

  • Diagnostic testwithout

    without

06

What researchers measure

Primary outcomes

  1. Accuracy of clinical-radiomic model for differentiating complicated from uncomplicated appendicitis

    ROC curve will be plotted and the area under ROC curve will be compared

    Time frame: January 2021 to December 2022

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jun 2023, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Jan 3, 2023
Primary completionEst.
Jun 3, 2023
CompletionEst.
Dec 3, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843630
Lead sponsor
Kecheng Zhang
Responsible party
Kecheng Zhang (Department of General Surgery, Chinese PLA General Hospital First Medical Center, Chinese PLA General Hospital) — Sponsor-investigator
First posted
May 6, 2023
Start date
Jan 3, 2023
Primary completion
Jun 3, 2023 (estimated)
Completion
Dec 3, 2023 (estimated)
Last update
May 6, 2023

Study contacts

LI LI
Contact
1192225348@qq.com
13210613213
Kecheng Zhang
principal investigator · Senior Department of General Surgery, Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion